Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Mol Cancer Ther. 2013 May 1;12(5):10.1158/1535-7163.MCT-12-1240. doi: 10.1158/1535-7163.MCT-12-1240

Figure 6. Response of PC3/2G7 tumors to long-term axitinib treatment.

Figure 6

A. Change in mean tumor volume for daily axitinib-treated tumors over a 58-day period, with tumor re-growth resuming after day 20. B. Body weight measurements in mice bearing PC3/2G7 xenografts. Horizontal red lines along X-axis mark the axitinib treatment period. C. Change in functional blood vessels assayed by Hoechst 33342 perfusion in PC3/2G7 tumors analyzed after 12 or 58 days axitinib treatment (magnification, × 4.2). D. Changes in microvessel density (CD31 staining; magnification, 4.2×) and cell proliferation (PCNA staining; magnification, 20×) in PC3/2G7 tumors after 58 days axitinib treatment. Increased neovascularization near the tumor periphery and increased tumor cell proliferation were apparent at day 58. See Supplemental Fig. 8 for additional images of neovascularization after 58 days axitinib treatment.